ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- siRNA-mediated silencing of placenta-specific protein 1 (PLAC1) alters CD4+, CD8+, and regulatory T cells in a murine colon cancer model.Scientific reports · 2026Article
- Integrin-Mediated Mechanosensing of Modeled Lymph Node Microenvironment Promotes T Cell Activation via Nuclear Deformation.Research (Washington, D.C.) · 2026Article
- Review
- Exploring the causal influence of 731 immune cells on 4 different glaucoma subtypes using a two-sample mendelian randomization method.Scientific reports · 2025Article
- Aptamer based immunotherapy: a potential solid tumor therapeutic.Frontiers in immunology · 2025Review
- Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome.Acta pharmaceutica Sinica. B · 2023Review
- Association between oxidative stress, mitochondrial function of peripheral blood mononuclear cells and gastrointestinal cancers.Journal of translational medicine · 2023Article
- RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.Cancer research · 2023Review
- Advancing cancer treatment:Frontiers in molecular biosciences · 2023Review
- Identification of G-quadruplex anti-Interleukin-2 aptamer with high specificity through SELEX stringency.Heliyon · 2022Article
- RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics.Molecular cancer · 2022Review
- DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo.Nature communications · 2021Article
- Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.Frontiers in oncology · 2021Review
- Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.Frontiers in cell and developmental biology · 2021Review
- Review
- Delivery of nucleic acid therapeutics for cancer immunotherapy.Medicine in drug discovery · 2020Article
- Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy.International journal of molecular sciences · 2020Review
- Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.Pharmaceutics · 2019Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Immune responses elicited against cancer using existing therapies such as vaccines or immune stimulatory antibodies are often not curative. One way to potentiate antitumor immunity is to enhance the long-term persistence of anti-tumor CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.